GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)
Hong Kong · Delayed Price · Currency is HKD 33.00
+3.42 (11.56%)
Sep 30, 2026, 4:08 PM HKT
HKG:2595 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 84 | 130.27 | 104.7 | 73.73 | |
Revenue Growth | -56.58% | 24.42% | 42.00% | - |
Cost of Revenue | 49.42 | 46.61 | 20.1 | 0.68 |
Gross Profit | 34.57 | 83.66 | 84.61 | 73.05 |
Selling, General & Admin | 71.73 | 81.38 | 58.08 | 49.95 |
Research & Development | 352.35 | 282.26 | 332.12 | 308.94 |
Operating Expenses | 424.08 | 363.64 | 390.21 | 358.88 |
Operating Income | -389.5 | -279.98 | -305.6 | -285.83 |
Interest Expense | -5.88 | -6.39 | -6.12 | -1.49 |
Interest & Investment Income | 58.05 | 31.18 | 17.23 | 10.77 |
Currency Exchange Gain (Loss) | -80.14 | -23.84 | 3.54 | 3.82 |
Other Non Operating Income (Expenses) | 0.45 | 3.32 | -4.97 | 21.75 |
EBT Excluding Unusual Items | -417.03 | -275.71 | -295.92 | -250.98 |
Gain (Loss) on Sale of Investments | 4.07 | 0.19 | 0.4 | 3.59 |
Gain (Loss) on Sale of Assets | -0.03 | -0.01 | -0.01 | -0.14 |
Other Unusual Items | -902.98 | -1,519 | -382.11 | -260.79 |
Pretax Income | -1,316 | -1,794 | -677.64 | -508.32 |
Income Tax Expense | 0.13 | 0.15 | - | - |
Net Income | -1,316 | -1,795 | -677.64 | -508.32 |
Net Income to Common | -1,316 | -1,795 | -677.64 | -508.32 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 468 | 296 | 259 | 220 |
Shares Outstanding (Diluted) | 468 | 296 | 259 | 220 |
Shares Change | 218.73% | 14.39% | 17.40% | - |
EPS (Basic) | -2.81 | -6.07 | -2.62 | -2.31 |
EPS (Diluted) | -2.81 | -6.07 | -2.62 | -2.31 |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | -372.68 | -135.81 | -206.64 | -202.65 |
Free Cash Flow Per Share | -0.80 | -0.46 | -0.80 | -0.92 |
Gross Margin | 41.16% | 64.22% | 80.81% | 99.07% |
Operating Margin | -463.72% | -214.93% | -291.87% | -387.66% |
Profit Margin | -1566.86% | -1377.58% | -647.20% | -689.40% |
Free Cash Flow Margin | -443.69% | -104.25% | -197.35% | -274.85% |
EBITDA | -385.02 | -274.53 | -297.1 | -274.33 |
EBITDA Margin | - | -210.74% | -283.76% | - |
D&A For EBITDA | 4.48 | 5.46 | 8.5 | 11.5 |
EBIT | -389.5 | -279.98 | -305.6 | -285.83 |
EBIT Margin | - | -214.93% | -291.87% | - |